August 14, 2025

Low Bone Quality in RA Tied to Diabetes, Study Shows

Trabecular bone score identifies high rates of vertebral bone quality loss in women with rheumatoid arthritis, regardless of corticosteroid use.

Conexiant

August 11, 2025

FDA Approves Ketamine Product for Surgical Pain Management

PharmaTher has received FDA approval for KETARx, a ketamine therapy for surgical pain management.

Conexiant

August 04, 2025

Mood Shift Linked to Shoulder Pain Relief

Patients undergoing shoulder arthroplasty for rheumatoid arthritis show significant pain and function improvement, and data suggest emotional status may influence recovery dynamics over time.

Conexiant

July 31, 2025

FDA Approves Implantable Device for RA

“The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases."

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

June 12, 2025

Gene Variants Linked to CPPD Risk

A large genetic study in U.S. veterans has identified ENPP1 and RNF144B as genes associated with calcium pyrophosphate deposition disease, suggesting potential for targeted treatment approaches.

Conexiant

April 30, 2025

New AI Sensor Diagnoses Osteoarthritis and Rheumatoid Arthritis

A new AI-assisted gold sensor distinguished osteoarthritis from rheumatoid arthritis with 98.1% accuracy by analyzing synovial fluid, offering a fast, noninvasive diagnostic option, researchers report.

Conexiant

April 18, 2025

Gout Remission Linked to Lower Urate, Fewer Flares

Remission in gout after urate-lowering therapy was seldom after 1 but high after 5 years, finds a five-year NOR-Gout study tracking 211 patients.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant